Novartis withdraws its application to extend the marketing authorisation for Zometa
- Details
- Category: Novartis
The European Medicines Agency (EMEA) has been formally notified by Novartis Pharma AG of its decision to withdraw the application to extend the marketing authorisation to include a new indication for the medicinal product Zometa (zoledronic acid).
Nycomed significantly increases profitability
- Details
- Category: Nycomed
In the first nine months of 2007 Nycomed increased adjusted EBITDA by 29.4% to € 940.8 million compared to the same period of last year. The performance improvement is a result of strong pantoprazole sales in the US and repatriation of pantoprazole in certain markets while at the same time, spending levels were reduced.
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
- Details
- Category: Financial
Celgene Corporation (Nasdaq: CELG) and Pharmion Corporation (Nasdaq: PHRM) jointly announced the signing of a definitive merger agreement pursuant to which Celgene has agreed to acquire Pharmion. Under the terms of the merger agreement, Celgene will acquire all of the outstanding shares of Pharmion common stock for $72.00 per share payable in a combination of cash and shares of Celgene common stock. The transaction is expected to be slightly dilutive to earnings in 2008 and accretive in 2009 and beyond.
Menveo(TM) (MenACWY-CRM) vaccine to demonstrate an excellent immune response in infants
- Details
- Category: Novartis
New clinical data for the Novartis development vaccine Menveo(TM) [2] (MenACWY-CRM) show an excellent and broad immune response in infants as young as six months of age against four common serogroups (or types) of meningococcal meningitis, a potentially fatal bacterial disease involving inflammation of membranes around the brain and spinal cord.
Pfizer to Acquire Coley Pharmaceutical Group
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.
Abbott Partners With Operation Smile to Support 40 Medical Missions in 25 Countries
- Details
- Category: Abbott
Abbott (NYSE: ABT) is supporting Operation Smile's global initiative to help bring smiles to kids with facial deformities by providing treatment to an estimated 5,000 children in need of surgeries. The initiative, which is part of Operation Smile's 25th anniversary celebration - World Journey of Smiles - takes place this month and consists of 40 medical missions across 25 countries. Abbott has donated 1,700 bottles of its anesthesia product, valued at almost $500,000, for the surgeries.
Award recognises and rewards journalism that extends public awareness and understanding of COPD
- Details
- Category: Boehringer Ingelheim
The independent judging panel of the Eloquium Award has today named three journalists as winners of the 2007 competition for excellence in reporting on chronic obstructive pulmonary disease (COPD) the fastest growing cause of death in the world's most advanced economies. Currently, 600 million people live with COPD which is projected to become the worldâs third-leading cause of death by 2020.[1,2]
More Pharma News ...
- Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics
- Novo Nordisk celebrates first ever UN-observed World Diabetes Day
- Novel agent for treatment of Parkinson's disease in clinical development
- New Phase III Trial Results for Rivaroxaban
- Novo Nordisk launches Changing Diabetes Barometer
- Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
- Bayer Temporarily Suspends Global Trasylol® Marketing